Search

Author/Creator Heilbrun, Lance

1. A study of circulating microRNAs identifies a new potential biomarker panel to distinguish aggressive prostate cancer. (17th February 2018)

Authors:
Farran, Batoul; Dyson, Gregory; Craig, Douglas; Dombkowski, Alan; Beebe-Dimmer, Jennifer L; Powell, Isaac J; Podgorski, Izabela; Heilbrun, Lance; Bolton, Susan; Bock, Cathryn H
Journal:
Carcinogenesis
Issue:
Volume 39:Number 4(2018)
Page Start:
556
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy‐Naive Metastatic Castrate‐Resistant Prostate Cancer. (31st May 2019)

Authors:
Heath, Elisabeth; Heilbrun, Lance; Mannuel, Heather; Liu, Glenn; Lara, Primo; Monk, J. Paul; Flaig, Thomas; Zurita, Amado; Mack, Philip; Vaishampayan, Ulka; Stella, Philip; Smith, Daryn; Bolton, Susan; Hussain, Arif; Al‐Janadi, Anas; Silbiger, Daniel; Usman, Muhammad; Ivy, S. Percy
Journal:
Oncologist
Issue:
Volume 24:Number 9(2019)
Page Start:
1149
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Pilot Phase II Trial of Bevacizumab Monotherapy in Nonmetastatic Castrate-Resistant Prostate Cancer. (13th June 2012)

Authors:
Ogita, Shin; Tejwani, Sheela; Heilbrun, Lance; Fontana, Joseph; Heath, Elisabeth; Freeman, Stacy; Smith, Daryn; Baranowski, Karen; Vaishampayan, Ulka
Other Names:
Honoré S. Academic Editor.; Luber B. Academic Editor.
Journal:
ISRN oncology
Issue:
Volume 2012(2012)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗